Molecular and Immunohistochemical Analysis of the Prognostic Value of Cell-Cycle Regulators in Urothelial Neoplasms of the Bladder

European Urology

Volumn 50, Issue 3, 2006, Pages 506-515

  Yurakh, Andriy O ^a   Ramos, David ^b   Calabuig Fariñas, Silvia ^b   López Guerrero, José Antonio ^c   Rubio, José ^c   Solsona, Eduardo ^c   Romanenko, Alina M ^a   Vozianov, Alexander F ^a   Pellin, Antonio ^b   Llombart Bosch, Antonio ^b  

^a STATE INSTITUTION NATIONAL RESEARCH CENTER FOR RADIATION MEDICINE OF THE NATIONAL ACADEMY OF MEDICAL SCIENCES OF UKRAINE   (Ukraine)

^b UNIVERSITY OF VALENCIA   (Spain)

^c INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Bladder cancer; Cyclin D1; Disease progression; MDM2; p14ARF; p15INK4B; p16INK4A; p21Waf1; p27kip1; p53; Recurrence; Retinoblastoma Protein

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P14; PROTEIN P14ARF; PROTEIN P15; PROTEIN P15INK4A; PROTEIN P16; PROTEIN P16INK4A; PROTEIN P16INK4B; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BLADDER TUMOR; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CELL CYCLE REGULATION; CHROMOSOME 9P; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE FREE INTERVAL; FEMALE; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MOLECULAR BIOLOGY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS; UROTHELIUM;

CARCINOMA; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RETINOBLASTOMA; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 33746902441     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.03.027     Document Type: Article

References (50)

1. Chin L., Pomerantz J., and DePinho R.A. The INK4a/ARF tumor suppressor: one gene-two products-two pathways. Trends Biochem Sci 23 (1998) 291-296
2. Serrano M. The INK4a/ARF locus in murine tumorigenesis. Carcinogenesis 21 (2000) 865-869
3. Epstein J.I., Amin M.B., Reuter V.R., and Mostofi F.K. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22 (1998) 1435-1448
4. Sambrook J., Fritch E.F., and Maniatis T. Molecular cloning: a laboratory manual (1989), Cool Spring Harbor Laboratory Press, Cool Spring Harbor, NY pp. 1659
5. Romanenko A., Morell-Quadreny L., Lopez-Guerrero J.A., et al. The INK4a/ARF locus: role in cell cycle control for renal cell epithelial tumor growth after the Chernobyl accident. Virchows Arch 445 (2004) 298-304
6. Lopez-Guerrero J.A., Pellin A., Noguera R., Carda C., and Llombart-Bosch A. Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest 81 (2001) 803-814
7. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93 (1996) 9821-9826
8. Ainsworth P.J., Surh L.C., and Coulter-Mackie M.B. Diagnostic single strand conformational polymorphism, (SSCP): a simplified non-radioisotopic method as applied to a Tay-Sachs B1 variant. Nucleic Acids Res 19 (1991) 405-406
9. Solsona E., Iborra I., Dumont R., Rubio-Briones J., Casanova J., and Almenar S. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000) 685-689
10. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259-1264
11. Tuna B., Yorukoglu K., Tuzel E., Guray M., Mungan U., and Kirkali Z. Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer. Pathol Res Pract 199 (2003) 323-328
12. Friedrich M.G., Riethdorf S., Erbersdobler A., et al. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. Eur Urol 39 (2001) 159-166
13. Kilicli-Camur N., Kilicaslan I., Gulluoglu M.G., Esen T., and Uysal V. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder. Pathol Int 52 (2002) 463-469
14. Gontero P., Casetta G., Zitella A., et al. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 38 (2000) 287-296
15. Rodriguez Alonso A., Pita Fernandez S., Gonzalez-Carrero J., and Nogueira March J.L. Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67. Actas Urol Esp 27 (2003) 132-141
16. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85 (1993) 53-59
17. Vatne V., Maartmann-Moe H., and Hoestmark J. The prognostic value of p53 in superficially infiltrating transitional cell carcinoma. Scand J Urol Nephrol 29 (1995) 491-495
18. Vatne V., Maartmann-Moe H., and Hoestmark J. Flow cytometric DNA and p53 analysis in superficially infiltrating bladder carcinoma. Anticancer Res 14 (1994) 2735-2738
19. Irie A., Uchida T., Ishida H., Matsumoto K., Iwamura M., and Baba S. p53 Mutation in bladder cancer patients in Japan and inhibition of growth by in vitro adenovirus-mediated wild-type p53 transduction in bladder cancer cells. Mol Urol 5 (2001) 53-58
20. Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J., et al. Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 45 (2004) 606-612
21. Rodriguez-Alonso A., Pita-Fernandez S., Gonzalez-Carrero J., and Nogueira-March J.L. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma. Eur Urol 41 (2002) 182-188 discussion 8-9
22. Popov Z., Hoznek A., Colombel M., et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80 (1997) 1472-1481
23. Rodriguez-Alonso A., Pita-Fernandez S., Gonzalez-Carrero J., and Nogueira-March J.L. Multivariate analysis of survival, recurrence, progression and development of mestastasis in T1 and T2a transitional cell bladder carcinoma. Cancer 94 (2002) 1677-1684
24. Shiina H., Igawa M., Shigeno K., et al. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology 56 (1999) 239-247
25. Tsuji M., Kojima K., Murakami Y., Kanayama H., and Kagawa S. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 79 (1997) 367-372
26. Lopez-Beltran A., Luque R.J., Alvarez-Kindelan J., et al. Prognostic factors in survival of patients with stage Ta and T1 bladder urothelial tumors: the role of G1-S modulators (p53, p21Waf1, p27Kip1, cyclin D1, and cyclin D3), proliferation index, and clinicopathologic parameters. Am J Clin Pathol 122 (2004) 444-452
27. Liukkonen T., Lipponen P., Raitanen M., et al. Evaluation of p21WAF1/CIP1 and cyclin D1 expression in the progression of superficial bladder cancer. Finbladder Group. Urol Res 28 (2000) 285-292
28. Stein J.P., Ginsberg D.A., Grossfeld G.D., et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90 (1998) 1072-1079
29. Chatterjee S.J., Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22 (2004) 1007-1013
30. Del Pizzo J.J., Borkowski A., Jacobs S.C., and Kyprianou N. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 155 (1999) 1129-1136
31. Ioachim E., Michael M., Stavropoulos N.E., et al. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features. Urol Int 73 (2004) 65-73
32. Santos L.L., Amaro T., Pereira S.A., et al. Expression of cell-cycle regulatory proteins and their prognostic value in superficial low-grade urothelial cell carcinoma of the bladder. Eur J Surg Oncol 29 (2003) 74-80
33. Shariat S.F., Tokunaga H., Zhou J., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014-1024
34. Takagi Y., Takashi M., Koshikawa T., Sakata T., and Ohshima S. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor. Int J Urol 7 (2000) 366-372
35. Tut V.M., Braithwaite K.L., Angus B., Neal D.E., Lunec J., and Mellon J.K. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67. Br J Cancer 84 (2001) 270-275
36. Friedrich M.G., Blind C., Milde-Langosch K., et al. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur Urol 40 (2001) 518-524
37. Kruger S., Mahnken A., Kausch I., and Feller A.C. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma. Eur Urol 47 (2005) 463-467
38. Kwong R.A., Kalish L.H., Nguyen T.V., et al. p14ARF protein expression is a predictor of both relapse and survival in squamous cell carcinoma of the anterior tongue. Clin Cancer Res 11 (2005) 4107-4116
39. Schmitz-Drager B.J., Kushima M., Goebell P., et al. p53 and MDM2 in the development and progression of bladder cancer. Eur Urol 32 (1997) 487-493
40. Grossman H.B., Liebert M., Antelo M., et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4 (1998) 829-834
41. Orlow I., LaRue H., Osman I., et al. Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence. Am J Pathol 155 (1999) 105-113
42. Kruger S., Mess F., Bohle A., and Feller A.C. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder. Int J Oncol 23 (2003) 41-48
43. Tsukamoto M., Matsuyama H., Oba K., Yoshihiro S., Takahashi M., and Naito K. Numerical aberrations of chromosome 9 in bladder cancer. A possible prognostic marker for early tumor recurrence. Cancer Genet Cytogenet 134 (2002) 41-45
44. Edwards J., Duncan P., Going J.J., Watters A.D., Grigor K.M., and Bartlett J.M. Identification of loci associated with putative recurrence genes in transitional cell carcinoma of the urinary bladder. J Pathol 196 (2002) 380-385
45. Maruyama R., Toyooka S., Toyooka K.O., et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61 (2001) 8659-8663
46. Dominguez G., Carballido J., Silva J., et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 8 (2002) 980-985
47. Goudopoulou A., Saetta A., Korkolopoulou P., et al. p53 mutations detection in urinary bladder cancer in the Greek population: application of the NIRCA assay. J Exp Clin Cancer Res 22 (2003) 99-105
48. Cordon-Cardo C., Dalbagni G., Saez G.T., et al. p53 mutations in human bladder cancer: genotypic versus phenotypic patterns. Int J Cancer 56 (1994) 347-353
49. Lorenzo Romero J.G., Salinas Sanchez A.S., Gimenez Bachs J.M., et al. p53 Gene mutations in superficial bladder cancer. Urol Int 73 (2004) 212-218
50. Oyasu R., Nan L., Szumel R.C., Kawamata H., and Hirohashi S. p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism. Mod Pathol 8 (1995) 170-176